export interface BlogPost {
  slug: string
  title: string
  seoTitle: string
  seoDescription: string
  date: string
  excerpt: string
  readTime: string
  category: string
  body: string
}

export const blogPosts: BlogPost[] = [
  {
    slug: 'retatrutide-vs-semaglutide-phase-2-data',
    title: 'Retatrutide vs Semaglutide: What the Phase 2 Data Actually Shows',
    seoTitle: 'Retatrutide vs Semaglutide Phase 2 Data — GLP-3 R vs GLP-1 S Comparison',
    seoDescription:
      'Side-by-side analysis of Retatrutide (GLP-3 R) Phase 2 vs Semaglutide (GLP-1 S) STEP trial data. Weight reduction, timeline, receptor mechanism differences explained.',
    date: '2026-03-20',
    excerpt:
      'The Phase 2 data for Retatrutide showed −28.7% body weight reduction at 48 weeks. Semaglutide hit −12.4% at 68 weeks. Here is what the receptor mechanism difference actually explains.',
    readTime: '7 min',
    category: 'Research Analysis',
    body: `
## The Numbers Side by Side

Retatrutide Phase 2 (NEJM, 2023): −28.7% at 48 weeks at the 12mg dose cohort.
Tirzepatide SURMOUNT-1: −22.5% at 72 weeks.
Semaglutide STEP-1: −14.9% at 68 weeks.

The magnitude gap is not marginal — it is nearly 2× for Retatrutide vs Semaglutide. Understanding the mechanism explains why.

## Three Receptors vs One

Semaglutide (GLP-1 S) is a selective GLP-1 receptor agonist. It binds GLP-1R and achieves its effects through:
- Insulin secretion potentiation (pancreatic beta cells)
- Appetite suppression (CNS GLP-1R: hypothalamus, brainstem)
- Gastric emptying delay (enteric nervous system)

Tirzepatide adds GIPR agonism. GIP receptor co-activation potentiates insulin secretion beyond GLP-1 alone and may attenuate GLP-1-induced nausea at equivalent doses.

Retatrutide (GLP-3 R) adds glucagon receptor agonism on top of the dual GLP-1/GIP mechanism. This third receptor axis drives elevated energy expenditure through hepatic glucose production modulation and thermogenic pathway activation — effects neither GLP-1 nor GIP agonism achieves.

## Why the Glucagon Axis Matters

Conventional concern with glucagon receptor agonism is hyperglycemia risk. The key insight in the Retatrutide mechanism is that GLP-1R co-activation suppresses glucagon-driven glycemic effects — the two axes balance. What remains is the energy expenditure benefit of glucagon signaling without the glycemic liability.

Research modeling suggests approximately 40% of Retatrutide's additional weight effect vs tirzepatide comes from the glucagon axis contribution to energy expenditure.

## Timeline Adjustment

Note the timeline difference: Retatrutide data is at 48 weeks; semaglutide at 68 weeks. Adjusting for timeline, the gap narrows slightly but remains substantial. The dose also differs — Retatrutide 12mg vs Semaglutide 2.4mg (weight-management dose). Direct molecular comparison is not 1:1, but the Phase 2 signal is clear.

## Research Implications

For research protocols exploring tri-receptor engagement vs mono-receptor baselines, Retatrutide represents the most data-rich compound in the class. Its Phase 2 profile established it as the strongest single-compound GLP signal in the current literature.
    `.trim(),
  },
  {
    slug: 'bpc-157-gut-repair-research',
    title: 'BPC-157 and Gut Repair: The Research Behind the Protocol',
    seoTitle: 'BPC-157 Gut Repair Research — Mechanism, Studies, and Protocol Role',
    seoDescription:
      'Deep dive into BPC-157 gut repair research: NO system interactions, VEGF receptor signaling, 40+ published studies, and why it pairs with GLP receptor agonist protocols.',
    date: '2026-03-15',
    excerpt:
      'BPC-157 has over 40 peer-reviewed publications studying its GI mucosal effects. Here is the mechanism research and why it belongs in a GLP-based protocol stack.',
    readTime: '6 min',
    category: 'Compound Deep Dive',
    body: `
## What BPC-157 Is

BPC-157 is a 15-amino-acid synthetic pentadecapeptide: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence corresponds to residues 62–76 of human gastric juice protein BPC (Body Protection Compound).

It is not a hormone, receptor ligand by primary mechanism, or growth factor. It is a research compound with documented interactions across multiple signaling systems.

## The NO System Connection

The most extensively studied mechanism for BPC-157 involves the nitric oxide (NO) system. Research in multiple GI tissue models shows BPC-157 modulates NO production — specifically through interactions with the L-arginine-NO pathway.

The significance: NO is a central regulator of GI mucosal blood flow, smooth muscle tone, and barrier function. BPC-157's NO interactions directly map to its documented mucosal protection effects in animal models.

## VEGF Receptor Upregulation

Secondary research streams document BPC-157's upregulation of VEGF receptor 2 (VEGFR2). VEGF signaling drives angiogenesis — new blood vessel formation — which is critical to tissue repair processes.

In wound healing models, BPC-157 treatment accelerated both angiogenesis markers and epithelial repair timing. The VEGFR2 interaction provides a mechanistic explanation for observations that were initially characterized purely at the tissue level.

## The Dopaminergic and Serotonergic Dimensions

BPC-157 research has also documented interactions with dopaminergic and serotonergic systems — particularly relevant given that the gut contains approximately 90% of the body's serotonin. These interactions may partially explain BPC-157's documented effects in stress-ulcer models.

## Why It Pairs with GLP Research

GLP-1R agonists reduce gastric motility and caloric throughput. In extended GLP-based research protocols, the reduction in mucosal turnover stimulation from reduced food intake creates a relevant context for GI mucosal integrity studies. BPC-157's documented mucosal protection effects in this context make it a logical research companion.

The pairing addresses a specific research question: can GI mucosal integrity be maintained during reduced-intake GLP protocols? BPC-157 is the most studied compound for this research application.

## The Publication Count

40+ peer-reviewed publications specifically addressing BPC-157 GI effects since the mid-1990s. The compound is not obscure in the research literature — it has a more substantial published base than most peptides at comparable price points.
    `.trim(),
  },
  {
    slug: 'ghk-cu-4000-genes-research',
    title: 'GHK-Cu: The Copper Peptide That Touches 4,000 Genes',
    seoTitle: 'GHK-Cu Research — 4,000 Gene Interactions, Collagen Synthesis, Anti-Aging Mechanisms',
    seoDescription:
      'GHK-Cu modulates over 4,000 human genes according to genomic analysis. Explore the collagen, elastin, and anti-inflammatory research behind this copper tripeptide.',
    date: '2026-03-10',
    excerpt:
      'A single 3-amino-acid copper complex that modulates approximately 31% of the human transcriptome. Here is what the genomic research on GHK-Cu actually found.',
    readTime: '5 min',
    category: 'Compound Deep Dive',
    body: `
## Three Amino Acids. Extraordinary Reach.

GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper(II). Three amino acids plus a copper ion. By structural comparison to the large biologics and receptor agonists that dominate peptide research, it is strikingly minimal.

The 2010 genomic analysis by Pickart et al. changed how researchers understood this compound. Using gene chip analysis, they found GHK-Cu modulates expression of 4,177 human genes — approximately 31% of the transcriptome — with a strongly biased profile.

## The Directional Bias

Of those 4,000+ genes, the modulation is not random noise. The pattern shows:
- Upregulation of tissue repair genes (collagen I, collagen III, elastin, decorin, fibronectin)
- Upregulation of antioxidant defense genes (superoxide dismutase, catalase)
- Downregulation of cancer-associated inflammatory pathway genes (NF-κB targets, various proto-oncogenes)

The directionality — toward repair and away from inflammatory damage — is the remarkable finding. It is consistent across multiple independent research groups.

## Collagen and Elastin Research

The structural matrix research on GHK-Cu is among the most replicated in cosmetic peptide science. Studies consistently show upregulation of Type I and Type III collagen gene expression in fibroblast models. Elastin — the protein responsible for skin recoil — is similarly upregulated.

Decorin, a proteoglycan that organizes collagen fibers into ordered structures, is also upregulated. The combined effect in tissue models is not just more collagen — it is better-organized collagen matrix.

## The Copper Question

Free copper is cytotoxic at concentrations relevant to cell research. The chelation to GHK is not incidental — it is mechanistically essential. The tripeptide scaffold controls copper delivery, preventing free-copper oxidative damage while enabling the receptor interactions that drive gene expression changes.

This is why CuSO₄ or other free copper sources do not replicate GHK-Cu's documented effects. The specific molecular architecture is the active compound.

## Research-Grade vs Cosmetic Applications

GHK-Cu appears in cosmetic formulations at low concentrations. Research-grade GHK-Cu (>98% HPLC) is a distinct product class — supplied as lyophilized powder for laboratory studies at concentrations cosmetic products cannot achieve. The research literature cited above used laboratory-grade material.
    `.trim(),
  },
  {
    slug: 'peptide-reconstitution-guide',
    title: 'How to Reconstitute Research Peptides: A Complete Laboratory Guide',
    seoTitle: 'Peptide Reconstitution Guide — Bacteriostatic Water, Dosing, Storage',
    seoDescription:
      'Complete guide to reconstituting research peptides with bacteriostatic water: concentration calculations, storage conditions, multi-draw technique, and common mistakes.',
    date: '2026-03-05',
    excerpt:
      'Bacteriostatic water, concentration math, storage conditions, and multi-draw technique. The complete reconstitution reference for research peptide protocols.',
    readTime: '8 min',
    category: 'Research Guide',
    body: `
## What Reconstitution Is

Lyophilized (freeze-dried) research peptides are supplied as a dry powder to maximize stability during shipping and storage. Reconstitution is the process of dissolving this powder in a liquid to create a solution at a known concentration.

The standard reconstitution solvent for research peptides is bacteriostatic water (BW) — sterile water containing 0.9% benzyl alcohol as a bacteriostatic preservative.

## Why Bacteriostatic Water, Not Sterile Water

Sterile water is single-use. Once a vial is punctured, microbial contamination risk increases with each additional draw. Bacteriostatic water's 0.9% benzyl alcohol prevents microbial growth, enabling multi-draw use across research protocols without sterility compromise.

**Never reconstitute with tap water, distilled water, or saline.** These are not appropriate solvents for research peptide reconstitution.

## Concentration Calculations

The standard reconstitution math:

**Formula:** mg of peptide ÷ volume of BW (ml) = mg/ml concentration

**Example:** 10mg peptide + 2ml BW = 5mg/ml solution

For research requiring smaller volume draws, a more concentrated solution may be appropriate:
- 10mg + 1ml BW = 10mg/ml
- 10mg + 2ml BW = 5mg/ml
- 15mg + 2ml BW = 7.5mg/ml

Choose your concentration based on your research protocol's volume requirements. Most researchers target 100–200μl per draw for standard insulin syringe compatibility.

## Reconstitution Technique

1. Allow the lyophilized vial to reach room temperature before opening (reduces condensation)
2. Clean both the peptide vial cap and BW vial cap with an alcohol swab
3. Draw the required volume of BW into the syringe
4. Insert needle through peptide vial rubber stopper
5. **Drip the BW down the inside wall of the vial — do not spray directly onto the powder**
6. Gently swirl (do not shake) until fully dissolved
7. The solution should be clear; cloudiness indicates incomplete dissolution or degradation

## Storage After Reconstitution

| Condition | Duration |
|---|---|
| Refrigerated (2–8°C) | Up to 4 weeks |
| Room temperature | Not recommended |
| Frozen (−20°C) | Not recommended post-reconstitution |

Lyophilized peptides store stably at −20°C for months to years. Reconstituted solutions should be refrigerated and used within the indicated window.

## Common Mistakes

**Shaking the vial:** Mechanical agitation can denature peptide secondary structure. Always swirl gently.

**Adding BW too fast:** Rapid addition can cause foaming or incomplete mixing. Slow drip technique ensures clean dissolution.

**Drawing from a frozen reconstituted solution:** Freeze-thaw cycles damage peptide integrity in solution. If you need to pause a protocol, lyophilize (or purchase fresh) rather than freezing the reconstituted solution.

**Incorrect concentration math:** Double-check your math before proceeding. A 2× concentration error compounds directly into dosing accuracy.
    `.trim(),
  },
]

export function getAllBlogSlugs() {
  return blogPosts.map((p) => p.slug)
}

export function getBlogPostBySlug(slug: string): BlogPost | undefined {
  return blogPosts.find((p) => p.slug === slug)
}
